Solid Biosciences (NASDAQ:SLDB) Price Target Cut to $14.00 by Analysts at Wedbush

Key Points

• Wedbush has lowered the price target for Solid Biosciences (NASDAQ:SLDB) from $17.00 to $14.00 while maintaining an "outperform" rating, indicating a potential upside of 125.26% from its current price.
• Solid Biosciences's stock recently increased by 2.9% to $6.22, with a 12-month low of $2.41 and a high of $10.37.
• Institutional investors hold approximately 81.46% of the company's stock, with several firms significantly increasing their positions during the second quarter.

Solid Biosciences (NASDAQ:SLDB - Get Free Report) had its price target dropped by research analysts at Wedbush from $17.00 to $14.00 in a research note issued to investors on Wednesday,Benzinga reports. The brokerage currently has an "outperform" rating on the stock. Wedbush's price objective indicates a potential upside of 132.17% from the company's current price. Wedbush also issued estimates for Solid Biosciences' Q3 2025 earnings at ($0.38) EPS, Q4 2025 earnings at ($0.40) EPS, FY2025 earnings at ($1.75) EPS, Q1 2026 earnings at ($0.41) EPS, Q2 2026 earnings at ($0.37) EPS, Q3 2026 earnings at ($0.38) EPS, Q4 2026 earnings at ($0.39) EPS, FY2026 earnings at ($1.56) EPS, FY2027 earnings at ($1.58) EPS, FY2028 earnings at ($1.26) EPS and FY2029 earnings at ($0.50) EPS.

A number of other research analysts also recently commented on SLDB. Chardan Capital lowered their price objective on shares of Solid Biosciences from $16.00 to $15.00 and set a "buy" rating on the stock in a research report on Monday, May 19th. HC Wainwright restated a "buy" rating and set a $20.00 price target on shares of Solid Biosciences in a report on Tuesday, June 17th. Piper Sandler dropped their price target on shares of Solid Biosciences from $20.00 to $17.00 and set an "overweight" rating on the stock in a research note on Friday, May 16th. Cantor Fitzgerald set a $16.00 price objective on Solid Biosciences and gave the company an "overweight" rating in a research report on Monday, July 21st. Finally, JMP Securities restated a "market outperform" rating and issued a $15.00 target price on shares of Solid Biosciences in a research note on Friday, June 6th. One equities research analyst has rated the stock with a hold rating, ten have assigned a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat.com, Solid Biosciences has a consensus rating of "Buy" and a consensus price target of $15.00.

Solid Biosciences Stock Down 1.3%

NASDAQ SLDB traded down $0.08 on Wednesday, reaching $6.03. 858,887 shares of the stock traded hands, compared to its average volume of 1,935,939. Solid Biosciences has a 12 month low of $2.41 and a 12 month high of $10.37. The company has a market cap of $469.56 million, a price-to-earnings ratio of -2.15 and a beta of 2.44. The firm's fifty day simple moving average is $5.62 and its 200 day simple moving average is $4.45.

Solid Biosciences (NASDAQ:SLDB - Get Free Report) last announced its earnings results on Tuesday, August 12th. The company reported ($0.42) EPS for the quarter, beating the consensus estimate of ($0.51) by $0.09. As a group, equities research analysts forecast that Solid Biosciences will post -2.84 EPS for the current fiscal year.

Hedge Funds Weigh In On Solid Biosciences

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Bridgeway Capital Management LLC raised its position in Solid Biosciences by 18.0% in the 2nd quarter. Bridgeway Capital Management LLC now owns 98,531 shares of the company's stock valued at $480,000 after buying an additional 15,000 shares during the last quarter. Birchview Capital LP grew its stake in shares of Solid Biosciences by 38.8% during the 2nd quarter. Birchview Capital LP now owns 178,768 shares of the company's stock worth $871,000 after acquiring an additional 50,000 shares in the last quarter. Bank of America Corp DE raised its holdings in shares of Solid Biosciences by 2,150.4% in the second quarter. Bank of America Corp DE now owns 824,600 shares of the company's stock valued at $4,016,000 after purchasing an additional 787,957 shares during the last quarter. Nantahala Capital Management LLC lifted its position in shares of Solid Biosciences by 505.4% in the second quarter. Nantahala Capital Management LLC now owns 1,703,336 shares of the company's stock worth $8,295,000 after purchasing an additional 1,421,968 shares in the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in shares of Solid Biosciences by 168.1% in the second quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 36,143 shares of the company's stock worth $176,000 after purchasing an additional 22,663 shares in the last quarter. 81.46% of the stock is owned by institutional investors and hedge funds.

About Solid Biosciences

Solid Biosciences Inc, a life science company, develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, a gene transfer candidate for the treatment of Duchenne muscular dystrophy; and SGT-501 to treat Catecholaminergic polymorphic ventricular tachycardia.